No Detail Found!

Seroconversion of HBeAg in chronic Hepatitis “B”.Lamivudine Vs. placebo.

Author(s)
Muhammad Humayun Khyber Medical College, Peshawar, Pakistan
Faizur-Rahman Khyber Medical College, Peshawar, Pakistan
Intikhab Alam Khyber Medical College, Peshawar, Pakistan
Najeeb-Ul-Haq Khyber Medical College, Peshawar, Pakistan
Abstract
Chronic Hepatitis “B” With positive HBeAg is a replicative, progressive and infective stage of hepatitis “B” virus (HBV) induced chronic liver disease (CLD), with chances of rapid progression to cirrhosis liver and possible hepatocellular carcinoma (HCC). Seroconversion of HBeAg positive to HBeAg negative one and appearance of antibody to HBeAg (Anti HBeAb), possibly retards the course of progression of chronic liver disease, thus reducing the chances of development of cirrhosis liver and HCC. Spontaneous seroconversion is well known, but Lamivudine is considered to enhance this seroconversion in those with active disease. We randomly studied and compared the seroconversion rate spontaneously and with lamivudine in patients who were HBsAg / HBeAg positive for six months with a raised SGPT (ALT), and no ultrasonic evidence of cirrhosis liver. We found that lamivudine is effective in causing seroconversion and is well tolerated.
Publication Details
Page(s) 17-20
DOI DOI not available
Published Journal: Journal of Medical Science, Volume: 11, Issue: 1, Year: 2003

Request the full text from PASTIC

0

Citations

0

Downloads

38

Views